PBYI News and Press, Puma Biotechnology Inc From 12/15/22

Shares of Puma Biotechnology (NASDAQ: PBYI) were up as much as 13% this week. As of Thursday afternoon, they were still up more than 10% for the week, according to data from S&P Global Intelligence. The biotech company, which focuses on cancer therapies, closed at $4.40 a ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster (PD7-03), entitled “Neratini...

Shares of Puma Biotechnology (NASDAQ: PBYI) rose 20% on Monday. The stock closed trading Friday at $3.75 and opened at the same price on Monday. However, it rose to its 52-week high of $4.59 in the late afternoon before easing back to $4.50 at the close. The stock is up more than 48...

Puma Biotechnology, Inc. (PBYI) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Mariann Ohanesian - Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jef...

Puma Biotechnology ( NASDAQ: PBYI ) stock rose ~17% on Friday after Q3 results beat estimates and the company raised revenue outlook for its breast cancer drug Nerlynx. Q3 adjusted EPS rose to $0.05, compared to loss of -$0.99 in Q3 2021 ( consensus -$0.06...

Puma Biotechnology press release ( NASDAQ: PBYI ): Q3 Non-GAAP EPS of $0.05. Revenue of $57.1M (+23.6% Y/Y). Puma increased its financial guidance for full year 2022 to reflect improvements in U.S. demand for NERLYNX and changes to the timing of shipments to ...

Raises FY 2022 NERLYNX Net Product Revenue Guidance Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2022. Unless otherwise stated, all comparisons are for the third quarter of...

Puma Biotechnology ( NASDAQ: PBYI ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, after market close. The consensus EPS Estimate is $0.02 (+102.0% Y/Y) and the consensus Revenue Estimate is $50.47M (+9.2% Y/Y). Over the last 2 years, PBYI ha...

Puma Biotechnology ( NASDAQ: PBYI ) reported updated data from a phase 2 basket trial called SUMMIT of neratinib to treat patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC). Neratinib is approved in the U.S. under the name Nerlynx to...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung cancer (NSCLC) patients at the EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Sym...